Horizon Pharma Reports Sanofi Compiegne as Added Manufacturing Site for DUEXIS
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that the United States Food and Drug Administration has approved the use of Sanofi's manufacturing site in Compiegne, France to manufacture DUEXIS(R) (ibuprofen/famotidine), a proprietary single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg). Valeant Pharmaceuticals' manufacturing site in Laval, Quebec, previously owned and operated by Sanofi, serves as the primary commercial manufacturing site for DUEXIS.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.